| Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications A Wicki, D Witzigmann, V Balasubramanian, J Huwyler Journal of controlled release 200, 138-157, 2015 | 2121 | 2015 |
| The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs A Akinc, MA Maier, M Manoharan, K Fitzgerald, M Jayaraman, S Barros, ... Nature nanotechnology 14 (12), 1084-1087, 2019 | 1292 | 2019 |
| mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability L Schoenmaker, D Witzigmann, JA Kulkarni, R Verbeke, G Kersten, ... International journal of pharmaceutics 601, 120586, 2021 | 1171 | 2021 |
| The current landscape of nucleic acid therapeutics JA Kulkarni, D Witzigmann, SB Thomson, S Chen, BR Leavitt, PR Cullis, ... Nature nanotechnology 16 (6), 630-643, 2021 | 998 | 2021 |
| The role of lipid components in lipid nanoparticles for vaccines and gene therapy CH Albertsen, JA Kulkarni, D Witzigmann, M Lind, K Petersson, ... Advanced drug delivery reviews 188, 114416, 2022 | 578 | 2022 |
| PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application P Grossen, D Witzigmann, S Sieber, J Huwyler Journal of Controlled Release 260, 46-60, 2017 | 460 | 2017 |
| Lipid nanoparticle technology for clinical translation of siRNA therapeutics JA Kulkarni, D Witzigmann, S Chen, PR Cullis, R van der Meel Accounts of chemical research 52 (9), 2435-2444, 2019 | 432 | 2019 |
| On the role of helper lipids in lipid nanoparticle formulations of siRNA JA Kulkarni, D Witzigmann, J Leung, YYC Tam, PR Cullis Nanoscale 11 (45), 21733-21739, 2019 | 316 | 2019 |
| Lipid nanoparticle technology for therapeutic gene regulation in the liver D Witzigmann, JA Kulkarni, J Leung, S Chen, PR Cullis, R van der Meel Advanced drug delivery reviews 159, 344-363, 2020 | 311 | 2020 |
| Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery J Buck, P Grossen, PR Cullis, J Huwyler, D Witzigmann ACS nano 13 (4), 3754-3782, 2019 | 300 | 2019 |
| In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels T Rothgangl, MK Dennis, PJC Lin, R Oka, D Witzigmann, L Villiger, W Qi, ... Nature biotechnology 39 (8), 949-957, 2021 | 296 | 2021 |
| The biomolecular corona of lipid nanoparticles for gene therapy V Francia, RM Schiffelers, PR Cullis, D Witzigmann Bioconjugate chemistry 31 (9), 2046-2059, 2020 | 213 | 2020 |
| Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in microenvironment T Einfalt, D Witzigmann, C Edlinger, S Sieber, R Goers, A Najer, ... Nature communications 9 (1), 1-12, 2018 | 158 | 2018 |
| Zebrafish as a preclinical in vivo screening model for nanomedicines S Sieber, P Grossen, J Bussmann, F Campbell, A Kros, D Witzigmann, ... Advanced drug delivery reviews 151, 152-168, 2019 | 154 | 2019 |
| Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system R Pattipeiluhu, G Arias‐Alpizar, G Basha, KYT Chan, J Bussmann, ... Advanced Materials 34 (16), 2201095, 2022 | 131 | 2022 |
| Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads JA Kulkarni, D Witzigmann, J Leung, R van der Meel, J Zaifman, ... Nanoscale 11 (18), 9023-9031, 2019 | 127 | 2019 |
| Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo S Sieber, P Grossen, P Detampel, S Siegfried, D Witzigmann, J Huwyler Journal of Controlled Release 264, 180-191, 2017 | 108 | 2017 |
| Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach M Sedighi, S Sieber, F Rahimi, MA Shahbazi, AH Rezayan, J Huwyler, ... Drug delivery and translational research 9, 404-413, 2019 | 98 | 2019 |
| Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency MHY Cheng, J Leung, Y Zhang, C Strong, G Basha, A Momeni, Y Chen, ... Advanced Materials 35 (31), 2303370, 2023 | 96 | 2023 |
| In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA L Villiger, T Rothgangl, D Witzigmann, R Oka, PJC Lin, W Qi, S Janjuha, ... Nature biomedical engineering 5 (2), 179-189, 2021 | 92 | 2021 |
Joerg HuwylerUniversity of BaselDirección de correo verificada de unibas.ch
